Phase I Trial of a Novel Anti-GD2 Monoclonal Antibody, Hu14.18K322A, Designed to Decrease Toxicity in Children With Refractory or Recurrent Neuroblastoma

PURPOSE: The addition of immunotherapy, including a combination of anti-GD2 monoclonal antibody (mAb), ch14.18, and cytokines, improves outcome for patients with high-risk neuroblastoma. However, this therapy is limited by ch14.18-related toxicities that may be partially mediated by complement activ...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Navid, Fariba, Sondel, Paul M., Barfield, Raymond, Shulkin, Barry L., Kaufman, Robert A., Allay, Jim A., Gan, Jacek, Hutson, Paul, Seo, Songwon, Kim, KyungMann, Goldberg, Jacob, Hank, Jacquelyn A., Billups, Catherine A., Wu, Jianrong, Furman, Wayne L., McGregor, Lisa M., Otto, Mario, Gillies, Stephen D., Handgretinger, Rupert, Santana, Victor M.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2014
Témata:
ORIGINAL REPORTS
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4017710/
https://ncbi.nlm.nih.gov/pubmed/24711551
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2013.50.4423
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky